FDA Accepts Bevonescein (ALM-488) New Drug Application for Nerve Visualization During Head and Neck Surgery
Alume Biosciences announced on October 28, 2026, that the U.S. Food and Drug Administration has accepted for filing and review the company's New Drug Application for bevonescein (ALM-488), an investigational fluorescent drug intended to help surgeons visualize nerves in real time in adult patients undergoing head and neck surgery. Acceptance for filing is the step at which the FDA begins its substantive review of an application. It is not an approval.
Bevonescein is described by the company as a first-in-class investigational fluorescent peptide-dye conjugate, designed to provide fluorescent contrast between nerves and surrounding tissue during surgery when viewed with fluorescence-capable equipment such as analog surgical microscopes or filter-modified surgical loupes. It is included in this peptide regulatory tracker because the active product is built on a peptide conjugate, as the company describes it.
The company stated that the application is supported by a Phase 3 program comprising three clinical trials conducted across 13 institutions in 11 states. In all three trials, bevonescein-enabled visualization produced a statistically significant improvement in nerve conspicuity, a co-primary endpoint, compared with white light alone. In the pooled analysis, the company reported statistically significant improvements in visible nerve length and branching delineation and stated that across the Phase 3 program no serious drug-related adverse events and no deaths were reported.
The company also stated that bevonescein received FDA Fast Track Designation in 2022 and Breakthrough Therapy Designation in 2026, and that it will continue to work with the FDA during the review and prepare for a potential commercial launch if the product is approved. The company disclosure states that Breakthrough Therapy Designation does not guarantee or provide assurance of FDA approval or a shortened review timeline.
Bevonescein remains investigational. It has not been approved by the FDA or any other regulatory authority, and the company states that its safety and efficacy have not been established. The acceptance reported here starts a review. It does not make bevonescein an approved product, and any future approval would apply only to the specific product and labeled indication in the FDA decision.